EA201791258A1 - Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени - Google Patents

Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени

Info

Publication number
EA201791258A1
EA201791258A1 EA201791258A EA201791258A EA201791258A1 EA 201791258 A1 EA201791258 A1 EA 201791258A1 EA 201791258 A EA201791258 A EA 201791258A EA 201791258 A EA201791258 A EA 201791258A EA 201791258 A1 EA201791258 A1 EA 201791258A1
Authority
EA
Eurasian Patent Office
Prior art keywords
liver disease
acc
coa
acetyl
treatment
Prior art date
Application number
EA201791258A
Other languages
English (en)
Inventor
Джеральдин С. Харриман
Розана Капеллер-Либерманн
Вильям Ф. Вестлин
Х. Джеймс Харвуд
Original Assignee
Джилид Аполло, Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джилид Аполло, Ллс filed Critical Джилид Аполло, Ллс
Publication of EA201791258A1 publication Critical patent/EA201791258A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В настоящем изобретении предложены способы лечения, стабилизации, или снижения тяжести, или замедления прогрессирования неалкогольной жировой болезни печени с применением ингибитора АСС отдельно или с одним или более дополнительными терапевтическими агентами.
EA201791258A 2015-01-09 2016-01-08 Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени EA201791258A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562101726P 2015-01-09 2015-01-09
PCT/US2016/012673 WO2016112305A1 (en) 2015-01-09 2016-01-08 Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
EA201791258A1 true EA201791258A1 (ru) 2017-12-29

Family

ID=56356482

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201791258A EA201791258A1 (ru) 2015-01-09 2016-01-08 Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени
EA201892625A EA201892625A1 (ru) 2015-01-09 2016-01-08 КОМБИНИРОВАННАЯ ТЕРАПИЯ С ПРИМЕНЕНИЕМ ИНГИБИТОРА АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201892625A EA201892625A1 (ru) 2015-01-09 2016-01-08 КОМБИНИРОВАННАЯ ТЕРАПИЯ С ПРИМЕНЕНИЕМ ИНГИБИТОРА АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ

Country Status (13)

Country Link
US (2) US20180021341A1 (ru)
EP (2) EP3597271A1 (ru)
JP (2) JP2018501276A (ru)
KR (1) KR20170102299A (ru)
CN (1) CN107106873A (ru)
AU (1) AU2016205138A1 (ru)
BR (1) BR112017014341A2 (ru)
CA (1) CA2972919A1 (ru)
EA (2) EA201791258A1 (ru)
HK (2) HK1243369A1 (ru)
MX (1) MX2017008844A (ru)
SG (1) SG11201705361PA (ru)
WO (1) WO2016112305A1 (ru)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1993360T3 (pl) 2005-12-28 2017-08-31 Vertex Pharmaceuticals Incorporated Stałe postacie n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4- dihydro-4-oksochinolino-3-karboksyamidu
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
EP3149156B1 (en) 2014-05-28 2021-02-17 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
IL293770B2 (en) 2015-07-06 2023-07-01 Gilead Sciences Inc Modulators of cot and methods of using them
KR20180082556A (ko) * 2015-11-25 2018-07-18 길리어드 아폴로, 엘엘씨 피라졸 acc 억제제 및 그의 용도
EA201890949A1 (ru) 2015-11-25 2018-12-28 Джилид Аполло, Ллс СЛОЖНОЭФИРНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
US10183951B2 (en) 2016-03-02 2019-01-22 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof
EP3452578B1 (en) 2016-05-05 2022-08-10 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CN117229994A (zh) 2016-11-04 2023-12-15 儿童医院医学中心 肝类器官疾病模型以及其制备和使用方法
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
JP7369033B2 (ja) * 2016-11-10 2023-10-25 ガルメド リサーチ アンド ディベロップメント リミテッド 線維症の治療
CN110062634A (zh) * 2016-11-10 2019-07-26 盖尔梅德研究与发展有限公司 非酒精性脂肪肝病患者中纤维化的抑制
US11767515B2 (en) 2016-12-05 2023-09-26 Children's Hospital Medical Center Colonic organoids and methods of making and using same
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US10759812B2 (en) 2017-01-22 2020-09-01 Sunshine Lake Pharma Co., Ltd. Thienopyrimidine derivative and use thereof in medicine
US11142531B2 (en) 2017-03-24 2021-10-12 Zhejiang Hisun Pharmaceutical Co., Ltd. Cyano substituted heteroarylpyrimidinone derivative, preparation method and use thereof
PT3600309T (pt) * 2017-03-28 2022-10-03 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças hepáticas
TW201900167A (zh) * 2017-03-28 2019-01-01 美商基利科學股份有限公司 治療肝疾病之方法
CN110520125A (zh) * 2017-04-12 2019-11-29 吉利德科学公司 治疗肝病的方法
AU2018253885B2 (en) * 2017-04-18 2024-04-11 Genfit Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agent
EP3609523B1 (en) * 2017-04-24 2022-03-02 Tsinghua University Use of autoinducer-related pathway in inducing apoptosis and anti-infective therapy
MA49456A (fr) * 2017-06-19 2020-04-29 Arena Pharm Inc Composés et procédés pour le traitement de nafld et de nash
CN111201234A (zh) * 2017-07-17 2020-05-26 南京瑞捷医药科技有限公司 新型化合物及其作为acc抑制剂的用途
CN110959007B (zh) * 2017-07-26 2022-07-01 南京圣和药业股份有限公司 作为acc抑制剂的化合物及其应用
CN109316601B (zh) * 2017-07-31 2021-11-09 武汉朗来科技发展有限公司 药物组合物及其用途
AU2018326785B2 (en) 2017-09-03 2023-03-02 Angion Biomedica Corp. Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors
US11033601B2 (en) * 2017-09-14 2021-06-15 The Regents Of The University Of Colorado, A Body Corporate Selective inhibition of V1b for treating fatty liver
AU2018345817B2 (en) 2017-10-06 2021-10-28 Gilead Sciences, Inc. Combination therapy comprising an ACC inhibitor
US11419918B2 (en) * 2017-11-06 2022-08-23 Shenzhen Turier Biotech Co., Ltd. Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide
CN107693514A (zh) * 2017-12-04 2018-02-16 威海贯标信息科技有限公司 一种鲁格列净组合物
SG11202007143UA (en) 2018-01-31 2020-08-28 Heparegenix Gmbh Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN111989103A (zh) * 2018-04-17 2020-11-24 勃林格殷格翰国际有限公司 药物组合物、其治疗方法和用途
AU2019257632A1 (en) * 2018-04-24 2020-11-26 Ph Pharma Co., Ltd. Use of neutrophil elastase inhibitors in liver disease
WO2019243315A1 (en) 2018-06-21 2019-12-26 Heparegenix Gmbh Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP3823968A1 (en) 2018-07-16 2021-05-26 HepaRegeniX GmbH Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2020037023A1 (en) * 2018-08-14 2020-02-20 Avolynt Method for treating primary sclerosing cholangitis
KR102614808B1 (ko) 2018-08-31 2023-12-19 화이자 인코포레이티드 Nash/nafld 및 관련 질환의 치료를 위한 조합물
MX2021002655A (es) * 2018-09-06 2021-05-27 Galmed Res And Development Ltd Terapia de combinacion para el tratamiento de enfermedad hepatica.
CN110950884B (zh) * 2018-09-27 2024-03-26 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
US20220041616A1 (en) * 2018-11-20 2022-02-10 The National Institutes of Pharmaceutical R&D Co., Ltd. Spiro compound and medical uses thereof
CN113302190A (zh) 2019-01-15 2021-08-24 吉利德科学公司 Fxr(nr1h4)调节化合物
AU2020225225B2 (en) 2019-02-19 2022-12-22 Gilead Sciences, Inc. Solid forms of FXR agonists
WO2020208205A1 (en) * 2019-04-10 2020-10-15 Genfit Combination therapy comprising compounds of formula (i) and glp-1 receptor agonists
US11091467B2 (en) 2019-05-08 2021-08-17 Aligos Therapeutics, Inc. Modulators of THR-β and methods of use thereof
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
JP7374233B2 (ja) 2019-07-02 2023-11-06 ▲広▼▲東▼▲東▼▲陽▼光▲薬▼▲業▼有限公司 立体配置を有するチエノピリミジン誘導体及び薬物におけるその応用
WO2021018820A1 (en) 2019-07-29 2021-02-04 Heparegenix Gmbh Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
CN110628810B (zh) * 2019-08-13 2022-06-28 浙江大学 一种提高植物光合效率的方法
CN114340632A (zh) * 2019-08-30 2022-04-12 赛特瑞恩股份有限公司 用于治疗或预防非酒精性脂肪性肝炎（nash）的药物组合物
WO2021133948A1 (en) 2019-12-23 2021-07-01 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders
CA3164361A1 (en) 2020-01-15 2021-07-22 Heparegenix Gmbh 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as mkk4 inhibitors for treating liver diseases
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
US20230117286A1 (en) * 2020-03-11 2023-04-20 Dong-A St Co., Ltd. Pharmaceutical composition for prevention or treatment of nonalcoholic steatohepatitis
WO2021202224A1 (en) 2020-03-30 2021-10-07 Gilead Sciences, Inc. Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
JP7446475B2 (ja) 2020-04-02 2024-03-08 ギリアード サイエンシーズ， インコーポレイテッド Ｃｏｔ阻害剤化合物を調製するためのプロセス
CN111407892A (zh) * 2020-04-08 2020-07-14 中国药科大学 Acsl4及其在nash中的应用
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
KR20230013126A (ko) 2020-05-21 2023-01-26 시오노기 앤드 컴파니, 리미티드 지방성 간질환의 치료용 의약
EP4000616A1 (en) 2020-11-17 2022-05-25 Inventiva Combination therapy for the treatment of a liver disease
WO2022192428A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
CN117120429A (zh) 2021-03-29 2023-11-24 吉利德科学公司 Khk抑制剂
TW202345826A (zh) 2021-06-04 2023-12-01 美商基利科學股份有限公司 治療nash之方法
TW202311256A (zh) 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
WO2023034381A1 (en) * 2021-08-31 2023-03-09 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Quantitative systems pharmacology methods for identifying therapeutics for disease states
WO2023047203A1 (en) * 2021-09-25 2023-03-30 Torrent Pharmaceuticals Ltd Combination of omzotirome and antidiabetic agent, antihypertensive agent or anti-dyslipidemic agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009259839A1 (en) * 2008-06-20 2009-12-23 Kinemed, Inc. Compositions for the treatment of fibrotic diseases or conditions
US20100113473A1 (en) * 2008-10-30 2010-05-06 Player Mark R Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor
WO2012090219A2 (en) * 2010-12-31 2012-07-05 Jubilant Biosys Ltd. Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors
AU2012335088B2 (en) * 2011-11-11 2017-08-24 Gilead Apollo, Llc ACC inhibitors and uses thereof
KR20160005365A (ko) * 2013-05-10 2016-01-14 님버스 아폴로, 인코포레이티드 Acc 억제제 및 이의 용도
US9765089B2 (en) 2013-05-10 2017-09-19 Gilead Apollo, Llc ACC inhibitors and uses thereof
KR20160006762A (ko) * 2013-05-10 2016-01-19 님버스 아폴로, 인코포레이티드 Acc 억제제 및 이의 용도
WO2014182943A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof

Also Published As

Publication number Publication date
EP3597271A1 (en) 2020-01-22
US20180021341A1 (en) 2018-01-25
HK1243369A1 (zh) 2018-07-13
CN107106873A (zh) 2017-08-29
US20190381045A1 (en) 2019-12-19
HK1246232A1 (zh) 2018-09-07
EP3242722A1 (en) 2017-11-15
JP2020109130A (ja) 2020-07-16
JP2018501276A (ja) 2018-01-18
EA201892625A1 (ru) 2019-07-31
BR112017014341A2 (pt) 2018-03-27
CA2972919A1 (en) 2016-07-14
WO2016112305A1 (en) 2016-07-14
SG11201705361PA (en) 2017-08-30
KR20170102299A (ko) 2017-09-08
EP3242722A4 (en) 2018-07-11
MX2017008844A (es) 2018-03-14
AU2016205138A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
EA201791258A1 (ru) Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени
EA202092590A1 (ru) Пиридазиноны в качестве ингибиторов parp7
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2017002567A1 (es) Composiciones para modular la expresión de c9orf72
EA201790998A1 (ru) Иммуннорегуляторные агенты
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EA201591509A1 (ru) Ингибиторы cdc7
EA201790806A1 (ru) Иммунорегулирующие средства
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
EA202091437A1 (ru) КОНСТРУКЦИИ ДЛЯ RNAi, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПОДАВЛЕНИЯ ЭКСПРЕССИИ PNPLA3
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
EA201990567A1 (ru) Комбинированная терапия с ингибиторами глутаминазы
PH12017501879A1 (en) Methods for treating cancer
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
MX2022012386A (es) Compuestos inhibidores de metaloenzimas.
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
BR112018005331A2 (pt) inibidores de pcna